Accretion Nutraveda IPO is a book-built issue worth ~₹25 Crore. Accretion Nutraveda IPO is a fresh issue of 0.19 crore shares of ₹24.77 crore. The IPO will open for subscription on January 27, 2026, and close on January 30, 2026.
The basis of allotment is expected to be finalised on February 2, 2026, with tentative listing scheduled on BSE SME on February 4, 2026. The price band for the Accretion Nutraveda IPO has been fixed at ₹122 to ₹129 per share.
Investors can bid for Accretion Nutraveda IPO with a minimum of 2 lots, having 2,000 shares. For retail investors, the minimum investment required is ₹2,58,000. For high-net-worth investors (bHNI), the lot size stands at 8 lots, equal to 8,000 shares, amounting to ₹10,32,000.
Sobhagya Capital Options Pvt Ltd is the book running lead manager (BRLM), and Kfin Technologies Ltd is the registrar of the issue. Detailed information is available at the Accretion Nutraveda IPO RHP.
Accretion Nutraveda IPO Objectives
The company proposes to use the funds raised from the fresh issue for the following:
- Purchase of machinery for automation in theexisting Manufacturing unit
- Buying machinery for anew manufacturing setup
- Financing the working capital requirements of the company
- General corporate purposes
About Accretion Nutraveda Limited
Incorporated in 2021, Accretion Nutraveda Limited operates in the manufacturing of Ayurvedic and nutraceutical products across a wide range of dosage forms, including tablets, capsules, oral liquids, powders, external preparations, and oils. It is a healthcare-focused organisation specialising in contract manufacturing, catering to both domestic and international markets, including countries such as Sri Lanka, Singapore, and the USA. The Company combines classical Ayurvedic principles with modern nutraceutical science to deliver a diverse portfolio of products.
Its product range encompasses film-coated and chewable tablets designed for liver care, gynaecological health, bone and joint support, and respiratory wellness. Capsule offerings include both hard gelatin and HPMC varieties targeting liver detoxification, women’s health, and cognitive enhancement. The Company also manufactures oral liquids, such as syrups, suspensions, and tonics, tailored for pediatric and geriatric use.
In addition, the Company produces traditional Ayurvedic powders (churans) for digestive health, medicated oils for musculoskeletal and dermatological applications prepared using authentic traditional methods, and a variety of external preparations, including balms, ointments, creams, and gels, aimed at pain relief, skincare, and hair care.
Industry Outlook
- India’s pharmaceutical industry is globally recognised for its generic medicines and low-cost vaccines, ranking third in production volume and 14th in value worldwide.
- The country has a well-established domestic pharmaceutical sector, supported by approximately 3,000 drug companies and around 10,500 manufacturing units.
- India is a leading biotechnology hub, ranked among the top 12 destinations globally and the third largest in the Asia-Pacific region, contributing 3–5% to the global biotech industry.
- India’s bioeconomy was valued at USD 137 billion in 2022, with projections aiming to reach USD 300 billion by 2030.
How To Apply for the Accretion Nutraveda IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Accretion Nutraveda IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of Accretion Nutraveda IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
Contact Details of Accretion Nutraveda IPO
27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand, Ahmedabad, Gujarat, India, 382213
Phone:+91- 9904366177
E-mail:compliance@accretionnutraveda..com
Accretion Nutraveda IPO Reservation
| Investor Category | Shares Offered | Percentage (%) |
| Market Maker Shares Offered | 96,000 | 5.00 |
| QIB Shares Offered | 9,08,000 | 47.29 |
| NII (HNI) Shares Offered | 2,76,000 | 14.37 |
| Retail Shares Offered | 6,40,000 | 33.33 |
| Total Shares Offered | 19,20,000 | 100.00 |
Accretion Nutraveda IPO Lot Size Details
| Application | Lots | Shares | Amount |
| Retail (Min) | 2 | 2,000 | ₹2,58,000 |
| Retail (Max) | 2 | 2,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 7,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 8,000 | ₹10,32,000 |
Accretion Nutraveda IPO Promoter Holding
Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel are the promoters of the company.
| Share Holding Pre-Issue | 100.00% |
| Share Holding Post Issue | 73.48% |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Key Performance Indicators for Accretion Nutraveda IPO
| KPI (As of Aug 31, 2025) | Value |
| ROE (%) | 81.22 |
| ROCE (%) | 36.98 |
| RoNW (%) | 48.85 |
| PAT Margin (%) | 16.33 |
| EBITDA Margin (%) | 22.79 |
Accretion Nutraveda IPO Registrar and Lead Managers
Accretion Nutraveda IPO Lead Managers
Sobhagya Capital Options Pvt Ltd.
Registrar for Accretion Nutraveda IPO
Kfin Technologies Ltd
Contact Number:+91 40 6716 2222
Email Address:apl.ipo@kfintech.com
Financial Performance of Accretion Nutraveda Limited
| Particulars (in Lakhs) | Year ending on March 31, 2025 | Year ending on March 31, 2024 | Year ending on March 31, 2023 |
| Revenue from Operations | 1600.18 | 500.52 | 290.31 |
| EBITDA | 364.66 | 120.60 | 59.12 |
| EBITDA Margin | 22.79% | 24.10% | 20.36% |
| Restated Profit After Tax | 261.28 | 82.19 | 28.06 |
| PAT Margin | 16.33% | 16.42% | 9.67% |
| Net worth | 534.87 | 108.49 | 26.31 |
| RoE (%) | 81.22% | 121.94% | 228.56% |
| RoCE (%) | 36.98% | 28.98% | 12.51% |
| Debt | 385.87 | 217.36 | 197.33 |
Accretion Nutraveda Peer Details
| Name of the company | Face value (₹) | EPS (Basic & Diluted) | PE | RONW (%) | NAV per share (₹) | Total income (₹ in lakhs) |
| Accretion Nutraveda Limited | 10 | 7.19 | • | 48.85% | 14.72 | 1,605.55 |
| Peer Group | ||||||
| Walpar Nutritions Ltd. | 10 | 1.80 | 23.94 | 11.27% | 13.65 | 6,026.19 |
| Influx Healthtech Limited | 10 | 7.31 | 25.93 | 36.72% | 5.31 | 10,498.68 |
Strengths and Opportunities of Accretion Nutraveda Limited
- Promoters and senior management have deep industry experience in healthcare and nutraceuticals.
- Rigorous quality control ensures product consistency, safety, and efficacy.
- Direct engagement maintains long-term, trusted partnerships.
- Well-defined processes ensure efficiency, scalability, and business continuity.
- Target new geographies, strengthen corporate client engagement, and leverage digital marketing.
- Shift toward direct exports to increase international market reach.
- Launch differentiated, trend-aligned nutraceutical products to drive growth.
Risks and Threats of Accretion Nutraveda Limited
- Delays or issues in production could lead to cancelled orders and breached agreements.
- Periodic audits and potential regulatory actions could impact operations.
- A slowdown or shutdown in manufacturing and R&D could affect output.
- Poor inventory control may harm a business's reputation and financial performance.
- Reliance on third-party transport for raw materials and product delivery poses risks.
- Pending lease, construction, and equipment procurement could postpone growth plans and raise costs.
- Challenges in attracting talent and exposure to natural disasters or epidemics may affect operations and financials.
